ArticleDiscover oncology2025
Leveraging diverse cell-death patterns to predict to predict prognosis and immunotherapy in hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, liver hepatocellular carcinoma (LIHC) is characterized by high morbidity, rapid progression and early metastasis. Although many efforts have been made to improve the prognosis of LIHC, the situation is still dismal. Inability to initiate the process of programmed cell death (PCD) is closely associated with cancer progression, thus influencing patients' prognosis. In this study, our purpose was to construct PCD-related prognostic signature for LIHC patients.
methodsThe list of PCD-related genes was obtained from GSEA gene sets. The gene set associated with survival time and survival status was screened by weighted correlation network analysis (WGCNA). Via Cox regression test and LASSO Cox regression model, prognostic signature was established and was then externally validated by ICGC-LIRI-JP dataset and GSE14520 dataset. The immune infiltration status and immune function of the signature were analyzed by ESTIMATE algorithm and ssGSEA algorithm. TIDE score, IPS and immune checkpoints expression and IC50 value were utilized to predict chemosensitivity and immunotherapy response. Moreover, GSE91061 dataset and PRJEB23709 dataset were enrolled to verify the predictive efficacy on immunotherapy response.
resultsA total of 89 genes correlated with survival time and survival status were screened out from 1249 PCD-related genes. Next, the prognostic signature consisting of GLA, CLTA, CHGA, ERP29, MAPK3, CDK5, NLE1, STYXL1 and SFN was constructed. And high-risk patients were related to an adverse prognosis in TCGA-LIHC cohort and ICGC-LIRI-JP cohort. The prognostic signature also showed moderate to high predictive accuracy and was an independent prognostic indicator for LIHC. In general, low-risk patients exhibited higher StromalScore, immune cell infiltration levels, IPS, IPS-PD1 blocker, IPS-CTLA4 blocker, immune checkpoints expression and HLA-related genes expression while lower TIDE score, which indicated low-risk group tended to profit from ICI treatment. Furthermore, responders to ICI treatment had a lower riskscore in GSE91061 cohort, which showed similar result with ours.
conclusionsOur study developed a novel prognostic signature comprising of 9 PCD-related genes, which could stratify the risk and effectively predict the prognosis and the immunotherapy response of LIHC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.